Jacobs Levy Equity Management Inc. Invests $2.41 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Jacobs Levy Equity Management Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 26,900 shares of the medical equipment provider's stock, valued at approximately $2,406,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. State of New Jersey Common Pension Fund D lifted its holdings in shares of Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after acquiring an additional 115 shares during the last quarter. Bleakley Financial Group LLC lifted its stake in shares of Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. Avantax Advisory Services Inc. lifted its stake in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. Foundry Partners LLC boosted its holdings in shares of Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the period. Finally, UMB Bank n.a. increased its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $132.67.

Lantheus Stock Performance

Lantheus stock traded down $0.09 during mid-day trading on Wednesday, hitting $76.74. The company's stock had a trading volume of 221,025 shares, compared to its average volume of 981,015. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The stock has a market cap of $5.31 billion, a PE ratio of 12.75 and a beta of 0.23. The company has a 50 day moving average of $96.20 and a 200-day moving average of $92.76.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same quarter in the previous year, the company posted $1.69 earnings per share. The company's revenue for the quarter was up .8% on a year-over-year basis. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.